08:37 AM EDT, 08/26/2025 (MT Newswires) -- Genmab ( GMAB ) said Tuesday that its investigational drug rinatabart sesutecan, or Rina-S, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration for the treatment of adults with recurrent or progressive endometrial cancer that has advanced after prior treatment with platinum chemotherapy and a PD-(L)1 therapy.

The FDA's decision was based on data from a phase 1/2 trial, in which Rina-S showed encouraging responses in heavily pretreated endometrial cancer patients.

Shares of Genmab ( GMAB ) were up more than 2% in recent Tuesday premarket activity.